Physician profile
Bailey Johnson-Rae
NPI 1043966674
$1,338.13
in general payments reported to CMS, 2019-2025
15 companies · $881 in 2025
The $881 reported for 2025 was more than what 95% of School (Nurse Practitioner) providers received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $457 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,338.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $202.83 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $183.64 | 2024-2025 | Auvelity |
| Shockwave Medical, INC | $176.02 | 2025 | |
| Novo Nordisk INC | $147.69 | 2024-2025 | Rybelsus, Ozempic |
| Viiv Healthcare Company | $115.44 | 2025 | Apretude |
| Abbvie INC. | $114.68 | 2024-2025 | |
| Lilly USA, LLC | $102.72 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $65.92 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $62.49 | 2024-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $60.76 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $33.41 | 2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $23.22 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.11 | 2025 | Trintellix |
| Millicent US INC | $14.49 | 2025 | Femlyv |
| Tms Neurohealth Centers INC. | $13.71 | 2025 | Tms Neurohealth Centers INC. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailey Johnson-Rae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.